

Clinical Policy: Ceritinib (Zykadia)

Reference Number: ERX.SPA.05

Effective Date: 04.01.17

Last Review Date: 05.20

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Ceritinib (Zykadia®) is a kinase inhibitor.

FDA Approved Indication(s)

Zykadia is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Zykadia is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Non-Small Cell Lung Cancer (must meet all):

1. Diagnosis of recurrent, advanced, or metastatic NSCLC;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Meets one of the following (a or b):
 - a. Disease is ALK positive;
 - b. Disease is ROS1 positive, and Zykadia is prescribed as first-line therapy;
5. Request meets one of the following (a or b):*
 - a. Dose does not exceed 450 mg (3 capsules or tablets) per day;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid – 6 months

Commercial – Length of Benefit

B. Inflammatory Myofibroblastic Tumor (off-label) (must meet all):

1. Diagnosis of inflammatory myofibroblastic tumor (a soft tissue sarcoma);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Disease is ALK positive;
5. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid – 6 months

Commercial – Length of Benefit

2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed February 11, 2020.
3. National Comprehensive Cancer Network Guidelines. Non-Small Cell Lung Cancer Version 2.2020. Available at www.nccn.org. Accessed February 11, 2020.
4. National Comprehensive Cancer Network Guidelines. Central Nervous System Cancers Version 3.2019. Available at www.nccn.org. Accessed February 11, 2020.
5. National Comprehensive Cancer Network Guidelines. Soft Tissue Sarcoma Version 6.2019. Available at www.nccn.org. Accessed February 11, 2020.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	01.17	02.17
Policy updated to include new FDA approval for use as first-line therapy for NSCLC. Approval duration modified from length of benefit to 6 months for initial and 12 months for re-auth.	06.17	08.17
2Q 2018 annual review: no significant changes; specialist involvement in care added; dose changed from 750 to 450 mg per day per PI; approval durations increased to length of benefit; references updated.	02.13.18	05.18
2Q 2019 annual review: NCCN designation of advanced NSCLC added; NCCN recommended use for Zykadia as first-line therapy for ROS1 positive NSCLC added; references reviewed and updated.	02.19.19	05.19
New FDA-approved oral tablets added.	04.09.19	05.19
2Q 2020 annual review: no significant changes; added Medicaid line of business with 6/12 month initial/continued authorization duration; references reviewed and updated.	02.11.20	05.20

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.